Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients - Top-Institutions - MDSpire

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • By

  • Guihong Wan

  • Nga Nguyen

  • Charles Lu

  • Sara Khattab

  • Boshen Yan

  • Munachimso Amadife

  • Bonnie W. Leung

  • Wenxin Chen

  • Ahmad Rajeh

  • Kimberly Tang

  • Christopher Thang

  • Genevieve Boland

  • Kerry L. Reynolds

  • Kun-Hsing Yu

  • Alexander Gusev

  • Nicole R. LeBoeuf

  • Shawn G. Kwatra

  • Yevgeniy R. Semenov

  • May 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • by Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab, Boshen Yan, Munachimso Amadife, Bonnie W. Leung, Wenxin Chen, Ahmad Rajeh, Kimberly Tang, Christopher Thang, Genevieve Boland, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Nicole R. LeBoeuf, Shawn G. Kwatra, Yevgeniy R. Semenov

  • May 22, 2026

Related Content

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms